IL10 and cancer: In line with these rodent experiments, administration of pegylated recombinant IL-10 (20 μg/kg) to human cancer patients induces systemic immune activation as reflected by elevations in various pro-inflammatory cytokines and expansion of both systemic and tumour-resident CD8+ T cells (18, 19).